Journal
DRUG DISCOVERY TODAY
Volume 10, Issue 15, Pages 1041-1047Publisher
ELSEVIER SCI LTD
DOI: 10.1016/S1359-6446(05)03512-9
Keywords
-
Categories
Ask authors/readers for more resources
Clear links between cancer and cellular signaling triggered by the insulin-like growth factor-I (IGF-I) receptor (IGF-IR) and its cognate ligands (IGF-I and IGF-II) have been reported throughout the past two decades. Experimental results suggest that the pharmaceutical targeting of this signaling pathway could be beneficial for the treatment of cancer. Here, more recent advances towards potentially clinically viable strategies to interfere with the function of IGF-IR will be discussed.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available